Newton, MA, United States of America

Christopher J Roy

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 2016-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Christopher J Roy

Introduction

Christopher J Roy is an accomplished inventor based in Newton, MA, with a focus on developing advanced synthetic nanocarriers. He holds two patents that contribute significantly to the field of immunology and drug delivery systems. His work is characterized by a commitment to enhancing immune responses through innovative compositions.

Latest Patents

Christopher's latest patents include the development of tolerogenic synthetic nanocarriers. This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses. This innovative approach has the potential to revolutionize treatments for various immune-related conditions.

Career Highlights

Christopher J Roy is currently associated with Selecta Biosciences, Inc., where he applies his expertise in nanotechnology and immunology. His contributions to the company have been instrumental in advancing their research and development efforts. His work exemplifies the intersection of science and technology in creating effective therapeutic solutions.

Collaborations

Some of Christopher's notable coworkers include Christopher C Fraser and Grayson B Lipford. Their collaborative efforts contribute to a dynamic research environment that fosters innovation and discovery.

Conclusion

Christopher J Roy's contributions to the field of immunology through his patents and work at Selecta Biosciences, Inc. highlight his role as a leading inventor in synthetic nanocarrier technology. His innovative approaches are paving the way for future advancements in immune therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…